^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD22-targeted CAR-T immunotherapy

    Related drugs:
    17d
    A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma (clinicaltrials.gov)
    P1/2, N=42, Active, not recruiting, Seattle Children's Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD22 (CD22 Molecule)
    |
    SCRI-CAR22v2
    25d
    Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies (clinicaltrials.gov)
    P1, N=20, Recruiting, Stanford University | Trial completion date: Nov 2025 --> Jul 2026 | Trial primary completion date: Nov 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    Kymriah (tisagenlecleucel-T) • firicabtagene autoleucel (CRG-022)
    1m
    UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis (clinicaltrials.gov)
    P1, N=21, Recruiting, Nanjing IASO Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Sheba Medical Center | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive
    2ms
    CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    2ms
    Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Tongji Hospital | Trial completion date: Oct 2027 --> Feb 2029 | Initiation date: Mar 2025 --> Feb 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    2ms
    Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov)
    P1, N=68, Recruiting, University of Colorado, Denver | N=20 --> 68 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19x22 CAR T
    3ms
    CD22 Redirected Autologous T Cells for ALL (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD22 (CD22 Molecule)
    3ms
    CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov)
    P1, N=53, Recruiting, University of Colorado, Denver | N=26 --> 53
    Enrollment change
    |
    CD19x22 CAR T
    3ms
    Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Sana Biotechnology | Recruiting --> Active, not recruiting | N=35 --> 6 | Trial primary completion date: Mar 2028 --> Dec 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    3ms
    Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, Ohio State University Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells
    4ms
    Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT (clinicaltrials.gov)
    P2, N=23, Completed, The First Affiliated Hospital of Soochow University
    New P2 trial